A production error at one of the factories that produces Johnson & Johnson’s covid-19 vaccine affected 15 million doses. The information has been confirmed to the agency Bluncleberg by two sources linked to the process, even though the pharmaceutical company has devalued the situation, ensuring that it will meet the objectives of the next deliveries.
The problem, which happened at an Emergent Biosolutions factory, which is producing the vaccine in Baltimore, United States, should not change the goal of vaccination in the country, which expects to have all adults vaccinated in May, according to information from President Joe Biden .
None of the doses used in the country originated in that factory, which has not yet been changed by the Food and Drug Administration (FDA).
In a statement, Johnson & Johnson stated that the batch produced failed the quality control test.
Quality control identified a batch that did not meet quality standards at Emergent BioSolutions, a location that has not yet been authorized to produce vaccines from Johnson & Johnson “, can be read in the note sent by the company’s spokesperson to Bloomberg.
In addition, the pharmaceutical company sent the information to the FDA, which now has to approve the restart of manufacturing at that location.
As for the European Union, which approved the vaccine in early March, it is not yet known what the consequences of this error are for the 200 million doses scheduled for delivery in the second quarter, which begins this Thursday.
The European pharmaceutical subsidiary, Janssen, will send the first doses of this single-dose vaccine on April 19, with Portugal expecting 1.25 million doses in the next three months.
As a single dose, the Johnson & Johnson vaccine may become central to the European fight against covid-19, which until now had three two-dose vaccines (AstraZeneca, Moderna and Pfizer).
Get the latest news delivered to your inbox
Follow us on social media networks